Gambro US revenue change costs $85 million:
This article was originally published in Clinica
Gambro will make a provision of $85 million for US laboratory unbilled receivables from October 1998 until March this year. The company has decided to change its revenue recognition policy, treating sales at a point when tests are billed out, rather than when they are performed.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.